Executive summary: US Patent 9,492,429 claims a topical bedtime treatment method for hyperhidrosis using a narrow set of stereoisomerically defined pyrrolidinium bromides (glycopyrrolate-linked analogs) at ~1.0% to 25% strength, applied to defined anatomic “superficial” sites, achieving ≥25% sweat reduction for at least 6 hours and matching the efficacy of a topical glycopyrrolate comparator at the same concentration, while positioning an “improved safety profile” versus topical glycopyrrolate. The estate is method-of-use focused with extensive dependent claim subranges (dose rate, % active, solvents such as ethanol or ethanol/isopropyl alcohol, and specific stereoisomer embodiments), which typically creates high design-around risk for applicants whose product is positioned as a bedtime topical with the same efficacy band and comparator logic.

US Patent 9,492,429: Scope, claims, and US patent estate for topical hyperhidrosis treatment (glycopyrrolate-comparison pyrrolidinium bromides)

What does US 9,492,429 claim for topical hyperhidrosis treatment methods?

Core claim structure (independent claims 1 and 8):
A method of treating or dosing hyperhidrosis in a mammalian subject by:

Timing: “before bedtime” (claim 1) with optional second morning dose (claim 6).
Administration route: topical administration to skin of an area suffering from hyperhidrosis.
Composition: pharmaceutically acceptable vehicle plus ~1.0% to ~25% of a defined compound having:
- stereochemistry at R stereoisomeric configuration at the 2 position
- R or RS configuration at 1′ and 3′ positions
- selection from a closed set of enumerated stereoisomers and mixtures including:
  - (2R) variants with either methoxycarbonylmethyl or ethoxycarbonylmethyl
  - (2R,3′R) variants with the same substituent options
  - all as pyrrolidinium bromides
Efficacy requirement: compared to untreated baseline, sweat production is reduced:
- by at least ~25%
- for at least ~6 hours
Comparator/equivalence requirement (key limiting element):
- sweat reduction is “substantially equivalent” to sweat reduction with a composition having the same concentration of glycopyrrolate
Safety framing: “improved safety profile compared to topical glycopyrrolate.”

Claim 1 vs claim 8: claim 1 is a “method of treating”; claim 8 is a “method of dosing” using the same technical limitations. Many dependent claims mirror this distinction but do not materially expand scope beyond the stated efficacy/timing/composition envelope.

The closed compound set in independent claims

The independent claims incorporate only compounds listed as (iii), (iv), (v), and (vii) in the provided claim set. Scope is therefore constrained to specific stereochemical and substituent combinations of the pyrrolidinium bromide scaffold, not to a broad “formula” class.

Key limitations that drive infringement risk

From a claim construction perspective, the infringement question typically turns on the following hard elements:

use of a topical composition containing the listed stereoisomer (or mixture thereof)
dosing before bedtime
achieving ≥25% sweat reduction for ≥6 hours
demonstrating substantial equivalence to topical glycopyrrolate at the same concentration
positioning as improved safety profile versus topical glycopyrrolate

Which dependent claim features narrow or multiply protection?

Dependent claims add practical formulation and use restrictions. The most commercially relevant “narrowing levers” are below.

What sweat reduction ranges and duration does the patent cover?

Claims 2, 3, 9-10 include non-exclusive ranges (i.e., dependent but still limiting if asserted):

Claim 2: sweat reduction ~25% to ~99%, duration ~8 to ~24 hours
Claim 3: sweat reduction ~30% to ~75%, duration ~8 to ~12 hours
Claim 4: sweat reduction ~45% to ~60%; formulation 5% solution in 70% ethanol
Claim 5: sweat reduction ~50%
Claim 12: sweat reduction ~50% (same concept attached to claim 8)

These ranges matter for claim charting: even if a competitor exceeds 25% for 6 hours, they may avoid a narrower dependent claim (if not meeting the specific dependent range), though the independent claim 1/8 may still read.

What anatomic sites are explicitly claimed?

Claim 2 (and claim 9) include a defined set of “superficial anatomic areas”:

hand palm
foot plantar
groin
axilla
facial

This is a meaningful geographic/design constraint for topical hyperhidrosis programs that target other sites.

What dosage forms and vehicles are listed?

Claim 2 (and claim 9) includes wide open dosage form categories:

solid/semi-solid/powder/gel/cream/lotion/foam/solution/suspension/emulsion.

This reduces route-based design-around options; route-to-market changes (e.g., switching to a spray, patch, or different topical form) still depend on whether the product falls within the listed dosage categories.

What concentration bands are claimed?

Independent: ~1.0% to ~25%
Claim 2/9: not a concentration band, but includes the general composition category
Claim 3/10: ~2% to ~10%
Claim 4/11: 5% solution in 70% ethanol This gives multiple claim “landing zones” for formulation strengths.

What solvent systems are claimed?

Claims 27-38 (and mirrors in 33-36 and 37-38) claim solvent/co-solvent limitations:

isopropyl alcohol or ethanol alone as solvent or co-solvent with water (claims 27, 33, 34, 33-36)
“solvent for the compound is ethanol alone” (claims 28, 34) These are highly actionable for formulation strategy because solvent choice is an easy variable for a design-around, but only if the competitor can depart from the specific solvent limitation without leaving the independent claim boundary.

What regimen pattern is claimed?

Independent covers “before bedtime” dosing.
Claim 6/13 adds: a second dose in the morning after awakening.

So a once-night-only dosing program is less exposed to the dependent morning-dose claims, but still exposed to the independent bedtime claim.

What stereoisomer is explicitly singled out?

Claims 15-24 and 25-26 and 29-32 and 37-38 provide explicit embodiments for:

(2R,3′R) plus either methoxycarbonylmethyl or ethoxycarbonylmethyl The compound scope is therefore fully pinned to the stereoisomer set already embedded in the independent claims.

What is the “glycopyrrolate equivalence” limitation and why does it matter?

The independent claims include a comparator requirement:

sweat production reduction from the accused method is “substantially equivalent” to reduction obtained using a topical glycopyrrolate composition at the same concentration.

This does two things:

Performance-based narrowing: It is not enough to reduce sweat. The method must align the performance with glycopyrrolate under matched concentration conditions.
Test design pressure: In litigation, this forces evidence tied to controlled baseline comparisons and glycopyrrolate comparator arms. It can become a key battleground for validity (written description/enablement and specification support) and infringement proof.

The “improved safety profile” element also functions as a potential narrowing point, even though safety is frequently litigated as a functional statement that may depend on disclosed examples and test data.

How many claim sets are there in US 9,492,429?

Based on the provided claim listing:

Two independent claims:
- Claim 1 (method of treating)
- Claim 8 (method of dosing)
Dependent claims split into mirrored feature sets:
- claims 2-7 follow features attached to claim 1
- claims 9-14 follow mirrored features attached to claim 8
Additional dependent claim sets cover:
- explicit stereoisomer embodiments (claims 15-26 and 29-32)
- solvent limitations (claims 27-38)

Practically, the estate offers multiple ways to plead infringement depending on the asserted product profile:

regimen timing
active concentration
sweat reduction magnitude and duration
anatomic site
solvent system
whether a morning second dose is used
which exact stereoisomer embodiment is used

When does US 9,492,429 lose exclusivity based on patent term?

No date information is provided in the prompt for US 9,492,429: no filing date, priority date, patent grant date confirmation, or any later regulatory exclusivity data is included. Without those data, a precise expiration timeline and any PTAB/terminal disclaimer adjustments cannot be produced from the information available here.

What is the Orange Book status of US 9,492,429?

No Orange Book product listing, reference listed drug (RLD) mapping, or listed drug/NDA/BLA identifiers are provided in the prompt. A reliable Orange Book status statement cannot be made from the provided claim text alone.

What FDA pathways and regulatory facts affect freedom-to-operate for this patent?

No FDA regulatory status is included in the prompt: no NDA number, dosage form, sponsor, active ingredient name as marketed, or any approval history is provided. Patent scope analysis here is limited to claim language, not regulatory alignment.

What generic entry risks exist for hyperhidrosis topical products vs glycopyrrolate?

Under US 9,492,429, “entry risk” is driven by whether a competitor can avoid one or more of the independent claim anchors:

bedtime topical dosing
stereoisomer-defined pyrrolidinium bromide at ~1.0% to 25%
≥25% reduction for ≥6 hours
substantially equivalent performance to topical glycopyrrolate at same concentration
“improved safety profile” positioning

Likely low-risk design choices (relative)

Not using the claimed stereoisomer set (most decisive design-around lever)
Avoiding bedtime-only positioning (but once-night-only is still bedtime)
Changing formulation away from claimed solvent systems could reduce exposure to solvent-dependent claims, but not to independent claim if the independent claim does not require a specific solvent

Likely high-risk design choices

using the same stereoisomeric active and concentration band, with a bedtime regimen intended to match glycopyrrolate performance, especially if marketed as safer than topical glycopyrrolate
targeting the same anatomic sites enumerated in dependent claims

How strong is the patent estate for this active versus broader hyperhidrosis topical IP?

The provided claim set is method-of-use oriented and heavily structured around:

a closed list of stereoisomer embodiments
a performance comparator to glycopyrrolate
a bedtime schedule
and multiple dependent constraints (concentration subranges, duration windows, solvent selection, and sites)

This tends to produce a tight infringement perimeter but a high leverage point in litigation if the accused product closely matches the claimed performance and comparator logic.

However, the strength in litigation depends on the specification’s support for:

stereochemistry and compound scope
the “substantially equivalent” performance threshold
“improved safety profile” evidence

Those specifics are not included in the prompt, so strength can only be assessed at the claim-structure level.

What patent litigation affects this patent?

No litigation docket, PTAB event, district court case, or settlement details are provided in the prompt. A litigation impact assessment cannot be generated from the claim text alone.

What formulations are protected by US 9,492,429?

Protected formulations are those used in the claimed method such that they:

contain the defined stereoisomeric pyrrolidinium bromide in the claimed concentration band
are administered topically before bedtime
achieve the claimed sweat reduction outcome and comparator equivalence

Dependent claim formulation coverage includes:

dosage forms broadly (gels, creams, lotions, foams, solutions, suspensions, emulsions)
the specific 5% solution in 70% ethanol limitation (claim 4/11)
solvent/co-solvent limitations around ethanol and isopropyl alcohol (claims 27-38)
tighter active loading bands (e.g., 2% to 10% in claims 3/10)

Design-around and claim-exposure matrix for products targeting topical hyperhidrosis

Product attribute	If product matches	Risk to infringe US 9,492,429
Active stereoisomer set	uses listed (2R)/(2R,3′R) pyrrolidinium bromides with specified ester side chain and bromide salt	High (independent claim anchor)
Active concentration	within ~1.0% to ~25%	High (independent claim anchor)
Dosing schedule	applied before bedtime; optionally second morning dose	High for independent (bedtime) and additional dependent (morning)
Target site	hand palm, foot plantar, groin, axilla, facial	Moderate (dependent claims 2/9)
Sweat reduction magnitude	≥25% reduction	High (independent anchor)
Duration	≥6 hours reduction	High (independent anchor)
Comparator	“substantially equivalent” to topical glycopyrrolate at same concentration	High (litigation battleground)
Solvent system	ethanol/isopropyl alcohol selection	Depends (solvent-dependent claims 27-38; independent may still apply)
Formulation type	gel/cream/solution/foam etc.	Moderate (dependent claim breadth)

What companies are challenging or competing for topical hyperhidrosis exclusivity?

No company identifiers, competitors, or challengers are provided in the prompt. A credible landscape map cannot be produced without names tied to the specific patent.

Key Takeaways

US 9,492,429 protects bedtime topical methods to treat hyperhidrosis using stereochemically defined pyrrolidinium bromide bromides at ~1.0% to ~25%, achieving ≥25% sweat reduction for ≥6 hours.
The most litigable limitation is performance relative to topical glycopyrrolate at the same concentration: “substantially equivalent” sweat reduction plus a stated “improved safety profile.”
Dependent claims add meaningful exposure dimensions: sweat reduction bands (30–75%, 45–60%, 50%), duration windows (8–12 hours, 8–24 hours), anatomic sites, optional morning second dose, and solvent systems (ethanol/isopropyl alcohol, ethanol alone) including a specific 5% in 70% ethanol embodiment.
Freedom-to-operate risk is highest for products that match both the claimed stereoisomer set and the bedtime/effect/comparator framing.

FAQs

1) Does US 9,492,429 require both “bedtime” dosing and a second morning dose to infringe?

No. The independent claims require before bedtime. The morning second dose is an added feature only in dependent claims.

2) Is a product outside the 2% to 10% range automatically non-infringing?

Not necessarily. The independent claims cover ~1.0% to ~25%. The 2% to 10% limitation appears in dependent claim coverage.

3) If a product reduces sweat by more than 99%, does it still meet dependent claim 2’s range?

Dependent claim 2 states ~25% to ~99%. Exceeding the stated upper bound may avoid that dependent range while independent claim 1/8 could still apply if the performance still meets the independent thresholds and comparator logic.

4) Can competitors avoid infringement by switching solvents from ethanol to another alcohol?

Switching solvents may reduce risk under solvent-dependent claims (27-38), but infringement of the independent claims would still depend on meeting the independent claim anchors including active identity, concentration, timing, efficacy, and glycopyrrolate equivalence.

5) What is the strongest claim element for limiting scope?

The combined requirement that the method’s sweat reduction is substantially equivalent to topical glycopyrrolate at the same concentration, while using the listed stereoisomeric compound, is the strongest scope limiter.

References

United States Patent No. 9,492,429. (Claim text provided in prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Botanix Sb	SOFDRA	sofpironium bromide	GEL, METERED;TOPICAL	217347-001	Jun 18, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014227923	⤷ Start Trial
Brazil	112015023153	⤷ Start Trial
Canada	2904724	⤷ Start Trial
China	105050596	⤷ Start Trial
China	109364066	⤷ Start Trial
Denmark	2968267	⤷ Start Trial
European Patent Office	2968267	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,492,429

Which drugs does patent 9,492,429 protect, and when does it expire?

Summary for Patent: 9,492,429